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 Nogalamycin is an anthracycline compound produced by Streptomyces nogalater. 
Anthracyclines have been shown to be highly effective against cancer tissues, and 
anthracyclines such as daunorubicin are at the center of many chemotherapy treatments. 
However, anthracyclines are also highly toxic, particularly to the heart, making it 
necessary for the continuing study of this group of compounds. Similar to other 
anthracyclines, nogalamycin also shows antitumor activity. However, also similar to 
many other anthracyclines, its cardiotoxicity precludes its use as a clinical drug. In the 
past, semisynthesis has been successful in producing anthracycline analogs that have 
greater efficacy and lower cardiotoxicity. However, the success rate has been very low, 
with only a handful of potential candidates out of thousands of new compounds ever 
making it to clinical trials. Therefore, a more efficient way of generating new 
anthracyclines is needed to find better chemotherapy drugs. Towards this end, we have 
expressed and purified several proteins in the nogalamycin biosynthesis gene cluster in 
order to better understand how nature produces these products and harness that 
knowledge for future bioengineering efforts. Specifically, we have focused on the 
enzymes involved in modification and synthesis of nogalamine, the amino sugar essential 











Anthracyclines are aromatic polyketides produced by many Streptomycetes. 
These compounds contain an aglycone chromophore with one or more deoxysugars, 
usually including an amino sugar typically attached at C-7 on ring A (Minotti & Menna 
et al., 2004). The first anthracyclines, doxorubicin (Figure 1a) and daunorubicin (Figure 
1b), were purified in the 1960s from Streptomyces peucetius (Weiss, 1992). Since their 
discovery, anthracyclines have proven to be among the most effective chemotherapy 
drugs available today. The drugs work by a variety of mechanisms including generation 
of reactive oxygen species and inhibition of topoisomerases (Gewirtz, 1999). Notably, the 
planar shape of anthracyclines allows for intercalation into DNA, with the charged amino 
sugars interacting with the minor groove of the double helix, resulting in interference in 
DNA-dependent RNA synthesis, (Nunn & Van Meervelt et al., 1991). However, while 
effective, these compounds are also highly toxic, particularly to heart tissue (Minotti & 
Menna et al., 2004). For this reason, anthracyclines have continued to be compounds of 
great interest. In particular, great efforts have been made to find and synthesize new 
anthracyclines with improved efficacy and lower cardiotoxicity. These efforts have been 
partly successful, and anthracyclines such as epirubicin (Figure 1c) and idarubicin 
(Figure 1d), semisynthetic derivatives of doxorubicin and daunorubicin, respectively, are 
in common use today as antitumor drugs (Minotti & Menna et al., 2004). 
The process of finding epirubicin and idarucin has led to the development of a 
large variety of new compounds, including over 2000 analogs of the original 
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anthracyclines daunorubicin and doxorubicin (Weiss, 1992). This is due to the great 
variability in the anthracycline structure, and even a modest change in the compound can 
lead to drastic differences in biological activity. For example, the aglycone core of 
anthracyclines can be modified in a variety of ways. Idarubicin is identical to 
daunorubicin with the exception of the lack of a methoxy group at C-4 on ring D (Minotti 
& Menna et al., 2004). This one change gives idarubicin activity against a greater variety 
of cancers and allows for oral administration of the drug (Borchmann & Hubel et al., 
1997; Toffoli & Sorio et al., 2000).  In vitro studies have also suggested that idarubicin is 
more effective than daunorubicin against cell lines that have developed multidrug 
resistance (Toffoli & Simone et al., 1994). Additionally, the sugar bound to C-7 of ring A 
can be modified in many ways. In epirubicin, which is otherwise identical to doxorubicin, 
the hydroxyl group at C-4’ of daunosamine is in an equatorial rather than an axial 
position (Minotti & Menna et al., 2004). This variation introduces pharmacokinetic and 
metabolic changes that lead to a cumulative dose limit of epirubicin that is twice that of 
doxorubicin (Robert, 1993). However, despite these improvements, these drugs still carry 
a significant risk for cardiotoxicity. In addition, with only a handful out of the 2000 
analogs ever making it to clinical trials, it becomes apparent that more efficient ways of 
producing novel anthracyclines are needed. It continues to be important to characterize 
and understand the natural synthesis of anthracyclines in order to harness nature’s 
pathways for the production of more effective and less toxic drugs.  
Nogalamycin 
Nogalamycin (Figure 2a) is an anthracycline discovered in 1965 from 
Streptomyces nogalater (Bhuyan & Smith, 1965). Unlike the other anthracyclines 
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previously discussed, nogalamycin has two sugars. One is nogalose, a neutral deoxysugar 
as opposed to the usual amino sugar, attached at the C-7 position on ring A. The second 
is an amino sugar found on ring D, bound at both C-1 via an O-glycosidic bond and a rare 
carbon-carbon bond at C-2 (Wiley, 1979). This latter unusual glycosyl bond effectively 
introduces two additional rings to the aglycone core. Additionally, this second sugar 
allows nogalamycin to interact with both the minor and major grooves of DNA, making 
the compound highly active against Gram-positive bacteria and several cancer cell lines 
(Liaw & Gao et al., 1989; Williams & Egli et al., 1990; Smith & Davies et al., 1995). 
Unfortunately, nogalamycin is also highly cytotoxic, never even making it to clinical 
trials (Li & Krueger, 1991). Due to its high activity, however, nogalamycin continued to 
be an attractive research candidate, and menogaril (Figure 2b) was semisynthetically 
derived from nogalamycin in the 1970s by the removal of the uncharged nogalose on C-7 
and a methyl ester group from C-10. While these changes led to greater anticancer 
activity and lower toxicity than doxorubicin, clinical trials of menogaril were halted at 
Phase II (Li & Krueger, 1991; Siitonen & Claesson et al., 2012).  
Much of the current effort is focused on semisynthesis and degradation to find 
new anthracyclines and modify existing anthracyclines, seeking novel compounds that 
are more effective and safer (Wiley, 1979; Li & Krueger, 1991). However, studying and 
understanding how anthracycline molecules are naturally produced can greatly help 
accomplish both goals. The gene cluster for biosynthesis of nogalamycin was identified 
and sequenced in the 1990s (Ylihonko & Tuikkanen et al., 1996; Torkkell & Kunnari et 
al., 2001). Since then, many of the proteins encoded have been identified and assayed 
(Torkkell & Kunnari et al., 2001). However, many of the late-stage glycosylation steps, 
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particularly the synthesis and modification of the sugars, are still unclear. Our work here 
was performed with the purpose of elucidating some of these steps. Ultimately, we aim to 
find the mechanism by which the carbon-carbon bond between C2 of the aglycone and 
C5 of the nogalamine is formed. To do this, we must first characterize how the amino 
sugar is made by S. nogalater. To this end, we have identified the proteins and steps 
involved in the biosynthesis of TDP-2-deoxynogalamine. 
Nogalamine 
 Figure 3 shows the structure of TDP-activated 2-deoxynogalamine. Bacterial 
sugars usually follow highly conserved biosynthesis pathways, beginning with TDP-
activated intermediates (Thibodeaux & Melancon et al., 2008). The nogalamycin gene 
cluster encodes proteins that show homology with conserved proteins in other bacteria, 
and hint that nogalamine follows a pathway similar to other bacterial sugars (Torkkell & 
Kunnari et al., 2001; Siitonen & Claesson et al., 2012). Specifically, while nogalamine as 
bound to nogalamycin contains a 2’ hydroxyl group, the presence of a 2’,3’-dehydratase 
(SnogH) and the absence of a 3’,4’-ketoisomerase suggest that the 2’ hydroxyl is first 
removed then reinstalled afterwards, perhaps after the attachment of nogalamine to the 
aglycone core (Siitonen & Claesson et al., 2012). Therefore, the enzymes encoded by 
snogJ, a thymidylyl transferase, snogK, a 4’,6’-dehydratase, and snogH, a 2’,3’-
dehydratase, most likely catalyze the first three steps in nogalamine biosynthesis 
(Torkkell & Kunnari et al., 2001; Siitonen & Claesson et al., 2012).  
Following these three steps, there is some ambiguity in the pathway. The 
stereochemistry of the product of the 3’-aminotransferase SnogI is unknown. However, 
based on similarity to other deoxy amino sugar pathways and the structure of 
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nogalamycin, we predict that SnogI will introduce an equatorial amino group (Hong & 
Zhao et al., 2008). Additionally, the gene cluster for nogalamycin encodes only one sugar 
epimerase, SnogF. Given that both nogalamine and nogalose are liked formed through L-
configured intermediates, it is necessary that both pathways must share this enzyme 
(Torkkell & Kunnari et al., 2001; Siitonen & Claesson et al., 2012). Nogalamine further 
requires a 4’-ketoreductase, and there are two such enzymes, SnogG and SnogC, encoded 
in the gene cluster (Torkkell & Kunnari et al., 2001, Metsa-Ketela & Niemi et al., 2008). 
It is unknown which enzyme is actually involved in nogalamine biosynthesis. Based on 
phylogenetic comparison with other deoxy amino sugar 4’-ketoreductases, we predict 
that SnogG is the enzyme involved in the synthesis of nogalamine. Finally, the 
nogalamycin gene cluster encodes two N-methyltransferases, SnogA and SnogX 
(Torkkell & Kunnari et al., 2001). It is unknown which methytransferase is needed for 
the methylation of nogalamine or which order the enzymes work in if both are needed. 
Therefore, we have expressed and purified the proteins involved for in vitro 
reconstitution of TDP-2-deoxynogalamine and performed assays to analyze the roles of 
SnogF, SnogG, SnogA, and SnogX in the biosynthesis of this sugar. 
 
MATERIALS AND METHODS  
Protein Expression and Purification 
 RfbB, TylX3, and EvaB were purified as previously reported in the literature 
(Takahashi & Liu et al., 2005 and 2006).  
Genomic DNA was isolated and purified from Streptomyces nogalater NRRL 
3035 using the Qiagen DNeasy Blood and Tissue kit. From this, snogF, snogG, snogA, 
!
! 8 
and snogX were cloned with 5’-ndeI and 3’-nheI restriction sites. The products were 
verified by sequencing at the UT DNA sequencing facility. Correct products were 
digested using NdeI/NheI then ligated into pET28b for expression with N-terminal His6-
tags. The resulting plasmids were used to transform BL21 (DE3), and positive clones 
were selected with 30 µg/mL kanamycin. The snogA and snogF cultures were induced at 
OD600 ≈ 0.6 with 100 µM IPTG and grown for 16 hr at 16 °C. The snogX culture was 
induced at OD600 ≈ 0.6 with 200 µM IPTG and grown for 16 hr at 30 °C. The snogG 
culture was induced at OD600 ≈ 0.6 with 200 µM IPTG and grown for 16 hr at 25 °C. 
Cultures were collected by centrifugation at 4500 x g at 4 °C. The cell pellets were then 
stored at -80 °C until lysis. 
 The cell pellets were thawed in room temperature water and resuspended in two 
volumes of lysis buffer (Table 1). After adding 1 mg/mL of lysozyme, cell suspensions 
were incubated on ice for 30 min. The suspensions were sonicated in 30-sec bursts with a 
one-min rest between each burst. The resulting suspensions were centrifuged at 20000 x g 
at 4 °C for 40 min. The supernatants were added to 6.5 mL of pre-packed, equilibrated 
Ni-NTA resin. The columns were washed with approximately 100 mL of wash buffer 
(Table 1) and then eluted using elution buffer (Table 1). Samples from each fraction 
were analyzed by SDS-PAGE, and fractions containing a significant amount of protein 
were pooled and dialyzed. The eluates were then concentrated to 5-8 mL using an 
Amicon stirred cell under N2. The concentrated proteins were frozen in liquid nitrogen 
and stored at -80 °C until assays were performed. Table 1 shows composition of all 
buffers used during the purification process. Buffer group A was used for SnogA, SnogF, 
and SnogX, and buffer group B was used for SnogG. All buffers were adjusted to pH 8.0. 
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Assays and HPLC 
 Step 1 for all assays was incubation of TDP-glucose with RfbB at 37 °C for 
approximately 45 min. The enzymes, as indicated in Table 2, were then incubated with 
the previous reaction at 30 °C for 30 min to one hour. In addition to the assays listed in 
Table 2, one additional assay was performed with RfbB, SnogF, and SnogG, and a 
second assay was performed with RfbB, SnogF, and TylC2 to investigate the substrate 
flexibility of SnogG. The reactions analyzed by HPLC on a Beckman System Gold 
apparatus equipped with a 125 Solvent Module and 166 UV Detector Module. A Dionex 
Carbopac PA1 4X150 mm analytical column fitted with a Dionex Carbopac PA1 4X50 
mm guard column was used. The column was run with a binary mobile phase composed 
of Solvent A (water) and Solvent B (500 mM ammonium acetate in water), and 
compounds were detected at 267 nm. Figure 4 shows the gradients, given as percent 
solvent B over time in minutes, used for HPLC, where 4a shows the gradient first used 
and 4b shows the gradient used to separate monomethylated and dimethylated TDP-2-
deoxynogalamine. Peaks were collected, and ESI-MS and one- and two-dimensional 
(COSY) 1H-NMR were used to identify products. 
 
RESULTS  
Figures 5-8 shows the HPLC traces for the assays listed in Table 2. As seen in 
Figure 5, incubation of the full set of enzymes (RfbB, TylX3, EvaB, SnogF, SnogG, 
SnogA, and SnogX) leads to the production of three compounds. The top trace in Figure 
5 shows two peaks, the earlier peak containing both 7 and 8, mono- and dimethylated 
nogalamine, respectively, while the later peak contains the intermediate 6. Using gradient 
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4b, the first peak was resolved into two separate peaks for 7 and 8, as seen in the bottom 
trace of Figure 5. Mass spectrometry data support these peak assignments, and 1H-NMR 
for 6 agree with previously published results. 
Figure 6 shows HPLC traces for assays concerning the roles of SnogF and SnogG 
in the production of TDP-2-deoxynogalamine. In assay 2, the absence of SnogA and 
SnogX produced only one peak corresponding to 6, but no peaks were detected for 7 and 
8. The peak for 6 also disappears without the presence of both SnogF and SnogG. In 
assay 3, without either SnogF or SnogG, a peak corresponding to 4 can be seen. When 
only SnogF was present, as in assay 4, a single peak corresponding to 4 and 5 was 
detected. When only SnogG was present, as in assay 5, compound 5 is no longer 
produced, and the peak corresponds only to 4. In all four assays, the peak corresponding 
to 2 could be seen later in the trace. Interestingly, when both SnogF and SnogG were 
present, a peak corresponding to 2b could also be seen. To further investigate this shunt 
pathway, the TDP-glucose/RfbB reaction was incubated with SnogF and SnogG or 
SnogF and TylC2, a different 4’-ketoreductase. As can be seen in Figure 7b, 2b was 
detected in the reaction with SnogG but not in the reaction with TylC2. Mass 
spectrometry data for 2b support these peak assignments, and 1H-NMR for 2b agree with 
previously published results for TDP-L-rhamnose. 
Figure 8 shows HPLC traces for assays concerning the role of SnogA and SnogX 
in the methylation of nogalamine. When only SnogX was present as in assay 6, only 6 
was produced, with very little methylated sugar detected. When only SnogA was present 
as in assay 7, both 6 and 7, the monomethylated sugar, were detected. As shown in assay 
1, the presence of both SnogA and SnogX leads to the production of 6, 7, and 8. To 
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further test the sequence of SnogA and SnogX, in assay 8, SnogX was added after an 
initial one-hour incubation with SnogA, and this led also to the production of 6, 7, and 8.  
 
CONCLUSION 
 Figure 9a shows the pathway for synthesis of TDP-2-deoxynogalamine based on 
our results. Specifically, from assays 1-5, we saw that SnogF alone produced 5, and 
SnogF and SnogG together produced 6. Additionally, we saw that SnogF and SnogG 
produced shunt products corresponding to rhamnose and nogalose biosynthesis, 
indicating that SnogF and SnogG are both substrate-flexible, suggesting that these 
enzymes are shared in the biosynthesis of both nogalamine and nogalose. We also saw 
SnogA alone was capable of producing the monomethylated sugar, but not the 
dimethylated sugar. However, SnogX by itself was not capable of accepting 6, the non-
methylated intermediate. However, SnogA followed by SnogX was capable of producing 
the final product, the dimethylated sugar. Thus, we have shown that both SnogA and 
SnogX are required for the dimethylation of nogalamine. Additionally, we have 
demonstrated that SnogA is responsible for the first methylation, followed by SnogX, and 
both methyltransferases can accept the TDP-deoxy sugar independent of the aglycone 
core. These results provide the necessary groundwork for future investigation into the 








Bhuyan, B. & Smith, C. (1965). Differential interaction of nogalamycin with DNA of 
varying base composition. Proceedings Of The National Academy Of Sciences Of 
The United States Of America, 54 (2), p. 566. 
Borchmann, P., Hubel, K., Schnell, R. & Engert, A. (1997). Idarubicin: a brief overview 
on pharmacology and clinical use. International Journal Of Clinical Pharmacology 
And Therapeutics, 35 (2), pp. 80--83. 
Gewirtz, D. (1999). A critical evaluation of the mechanisms of action proposed for the 
antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. 
Biochemical Pharmacology, 57 (7), pp. 727--741. 
Hong, L., Zhao, Z., Melancon, C. E., Zhang, H. & Liu, H. (2008). In vitro 
characterization of the enzymes involved in tdp-d-forosamine biosynthesis in the 
spinosyn pathway of saccharopolyspora spinosa. Journal Of The American 
Chemical Society, 130 (14), pp. 4954--4967. 
Li, L. H. & Krueger, W. C. (1991). The biochemical pharmacology of nogalamycin and 
its derivatives. Pharmacology & Therapeutics, 51 (2), pp. 239--255. 
Liaw, Y. C., Gao, Y. G., Robinson, H., Van Der Marel, G. A., Van Boom, J. H. & Wang, 
A. H. (1989). Antitumor drug nogalamycin binds DNA in both grooves 
simultaneously: molecular structure of nogalamycin-DNA complex. Biochemistry, 




Metsa-Ketela, M., Niemi, J., Mantsala, P. & Schneider, G. (2008). Anthracycline 
biosynthesis: genes, enzymes and mechanisms. Springer, pp. 101--140. 
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. (2004). Anthracyclines: 
molecular advances and pharmacologic developments in antitumor activity and 
cardiotoxicity. Pharmacological Reviews, 56 (2), pp. 185--229. 
Nunn, C. M., Van Meervelt, L., Zhang, S., Moore, M. H. & Kennard, O. (1991). DNA-
drug interactions: the crystal structures of d (TGTACA) and d (TGATCA) 
complexed with daunomycin. Journal Of Molecular Biology, 222 (2), pp. 167--177. 
Robert, J. (1993). Epirubicin. clinical pharmacology and dose-effect relationship. Drugs, 
45 (Suppl 2), pp. 20-30. 
Siitonen, V., Claesson, M., Patrikainen, P., Aromaa, M., Mantsala, P., Schneider, G. & 
Metsa-Ketela, M. (2012). Identification of late-stage glycosylation steps in the 
biosynthetic pathway of the anthracycline nogalamycin. Chembiochem, 13 (1), pp. 
120--128. 
Smith, C. K., Davies, G. J., Dodson, E. J. & Moore, M. H. (1995). Dna-nogalamycin 
interactions: the crystal structure of d (TGATCA) complexed with nogalamycin. 
Biochemistry, 34 (2), pp. 415--425. 
Takahashi, H., Liu, Y., Chen, H. & Liu, H. (2005). Biosynthesis of TDP-L-mycarose: the 
specificity of a single enzyme governs the outcome of the pathway. Journal Of The 




Takahashi, H., Liu, Y. & Liu, H. (2006). A two-stage one-pot enzymatic synthesis of 
TDP-L-mycarose from thymidine and glucose-1-phosphate. Journal Of The 
American Chemical Society, 128 (5), pp. 1432--1433. 
Thibodeaux, C. J., Melancon, C. E. & Liu, H. (2008). Natural-product sugar biosynthesis 
and enzymatic glycodiversification. Angewandte Chemie International Edition, 47 
(51), pp. 9814--9859. 
Toffoli, G., Simone, F., Gigante, M. & Boiocchi, M. (1994). Comparison of mechanisms 
responsible for resistance to idarubicin and daunorubicin in multidrug resistant lovo 
cell lines. Biochemical Pharmacology, 48 (10), pp. 1871--1881. 
Toffoli, G., Sorio, R., Aita, P., Crivellari, D., Corona, G., Bearz, A., Robieux, I., Colussi, 
A. M., Stocco, F. & Boiocchi, M. (2000). Dose-finding and pharmacologic study of 
chronic oral idarubicin therapy in metastatic breast cancer patients. Clinical Cancer 
Research, 6 (6), pp. 2279--2287. 
Torkkell, S., Kunnari, T., Palmu, K., Mantsala, P., Hakala, J. & Ylihonko, K. (2001). The 
entire nogalamycin biosynthetic gene cluster of streptomyces nogalater: 
characterization of a 20-kb DNA region and generation of hybrid structures. 
Molecular Genetics And Genomics, 266 (2), pp. 276--288. 
Weiss, R. B. (1992). The anthracyclines: will we ever find a better doxorubicin?. 19 (6), 
pp. 670--686. 
Wiley, P. F. (1979). Improved antitumor activity by modification of nogalamycin. 
Journal Of Natural Products, 42 (6), pp. 569--582. 
!
! 15 
Williams, L. D., Egli, M., Qi, G., Bash, P., Van Der Marel, G. A., Van Boom, J. H., Rich, 
A. & Frederick, C. A. (1990). Structure of nogalamycin bound to a DNA hexamer. 
Proceedings Of The National Academy Of Sciences, 87 (6), pp. 2225--2229. 
Ylihonko, K., Tuikkanen, J., Jussila, S., Cong, L. & Mantsala, P. (1996). A gene cluster 
involved in nogalamycin biosynthesis from streptomyces nogalater: sequence 
analysis and complementation of early-block mutations in the anthracycline 




APPENDIX A: TABLES 
Table&1:&Buffers&used&for&protein&purification.&
 Lysis Buffer Wash Buffer Elution Buffer 
Group A 
 
(SnogA, SnogF, SnogX) 
NaH2PO4 50 mM 50 mM 50 mM 
NaCl 300 mM 300 mM 300 mM 
Imidazole 10 mM 20 mM 250 mM 




NaH2PO4 50 mM 50 mM 50 mM 
NaCl 300 mM 300 mM 300 mM 
Imidazole 10 mM 20 mM 250 mM 
Glycerol 20% 20% 20% 
L-arginine 10 mM 10 mM 10 mM 
L-glutamate 10 mM 10 mM 10 mM 







Assay 1 2 3 4 5 6 7 8 9 
RfbB ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
TylX3 ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✖ 
EvaB ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✖ 
SnogF ✔ ✔ ✖ ✔ ✖ ✔ ✔ ✔ ✔ 
SnogG ✔ ✔ ✖ ✖ ✔ ✔ ✔ ✔ ✔ 
SnogA ✔ ✖ ✖ ✖ ✖ ✖ ✔ ✔ ✖ 
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